title: Safety, tolerability, and immunogenicity of a recombinant, genetically engineered, live-attenuated vaccine against canine blastomycosis.
abstract: Blastomycosis is a severe, commonly fatal infection caused by the dimorphic fungus Blastomyces dermatitidis in dogs that live in the United States, Canada, and parts of Africa. The cost of treating an infection can be expensive, and no vaccine against this infection is commercially available. A genetically engineered live-attenuated strain of B. dermatitidis lacking the major virulence factor BAD-1 successfully vaccinates against lethal experimental infection in mice. Here we studied the safety, toxicity, and immunogenicity of this strain as a vaccine in dogs, using 25 beagles at a teaching laboratory and 78 foxhounds in a field trial. In the beagles, escalating doses of live vaccine ranging from 2 × 10⁴ to 2 × 10⁷ yeast cells given subcutaneously were safe and did not disseminate to the lung or induce systemic illness, but a dose of < 2 × 10⁶ yeast cells induced less fever and local inflammation. A vaccine dose of 10⁵ yeast cells was also well tolerated in vaccinated foxhounds who had never had blastomycosis; however, vaccinated dogs with prior infection had more local reactions at the vaccine site. The draining lymph node cells and peripheral blood lymphocytes from vaccinated dogs demonstrated gamma interferon (IFN-γ), tumor necrosis factor alpha (TNF-α), and granulocyte-macrophage colony-stimulating factor (GM-CSF) specifically in response to stimulation with Blastomyces antigens. Thus, the live-attenuated vaccine against blastomycosis studied here proved safe, well tolerated, and immunogenic in dogs and merits further studies of vaccine efficacy.
authors.affiliation: Department of Pediatrics, University of Wisconsin-Madison, Madison, WI 53706, USA. mwuethri@wisc.edu
authors.forename: Marcel
authors.initials: M
authors.lastname: Wüthrich
authors.forename: Theerapong
authors.initials: T
authors.lastname: Krajaejun
authors.forename: Valerie
authors.initials: V
authors.lastname: Shearn-Bochsler
authors.forename: Chris
authors.initials: C
authors.lastname: Bass
authors.forename: Hanna I
authors.initials: HI
authors.lastname: Filutowicz
authors.forename: Alfred M
authors.initials: AM
authors.lastname: Legendre
authors.forename: Bruce S
authors.initials: BS
authors.lastname: Klein
mesh_terms: D000818:Animals; D001758:Blastomyces / Q000235:genetics / Q000276:immunology*; D001759:Blastomycosis / Q000473:pathology / Q000517:prevention & control / Q000662:veterinary*; D001769:Blood / Q000276:immunology; D004283:Dog Diseases / Q000473:pathology / Q000517:prevention & control*; D004285:Dogs; D005260:Female; D005657:Fungal Vaccines / Q000009:adverse effects / Q000235:genetics / Q000276:immunology*; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000378:metabolism; D007371:Interferon-gamma / Q000378:metabolism; D007963:Leukocytes, Mononuclear / Q000276:immunology; D008198:Lymph Nodes / Q000276:immunology; D008297:Male; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism; D014613:Vaccines, Attenuated / Q000009:adverse effects / Q000235:genetics / Q000276:immunology; D014614:Vaccines, Synthetic / Q000009:adverse effects / Q000235:genetics / Q000276:immunology; D037521:Virulence Factors / Q000235:genetics
chemical_list: D005657:Fungal Vaccines; D014409:Tumor Necrosis Factor-alpha; D014613:Vaccines, Attenuated; D014614:Vaccines, Synthetic; D037521:Virulence Factors; D007371:Interferon-gamma; D016178:Granulocyte-Macrophage Colony-Stimulating Factor